| NCT01756781 | phase1 | completed | 2013-05-01 | 2013-07-01 | Pfizer | A Drug-Drug Interaction Study To Investigate The Potential For Multiple Doses Of Palbociclib (PD-0332991) To Alter The Pharmacokinetics Of Oral Midazolam In Adult Healthy Women of Non-Childbearing Potential. |
| NCT02311946 | phase1 | completed | 2015-01-01 | 2015-04-01 | Pfizer | A Pilot Study To Investigate The Effect Of Concurrent Antacid Administration On The Bioavailability Of Six Experimental Formulations Of Palbociclib |
| NCT01684215 | phase2 | completed | 2012-10-19 | 2016-03-04 | Pfizer | A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer |
| NCT00141297 | phase1 | completed | 2004-09-01 | 2008-07-01 | Pfizer | A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer |
| NCT02297438 | phase3 | completed | 2015-03-23 | 2020-08-31 | Pfizer | A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4] |